Retinal hemorrhage secondary airbag-related ocular trauma.

J Trauma

Division of Ophthalmology, Howard University Hospital, Washington, DC 20060, USA.

Published: April 1995

A case is presented in which a driver, who was wearing a three-point restraint system, was involved in a collision that triggered deployment of the vehicle's driver's-side airbag. The victim complained of blurred vision after the crash and on examination was found to have suffered a retinal hemorrhage in his right eye. Since no other cause could be determined, his injury was considered to be a result of contact with the deploying airbag.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00005373-199504000-00019DOI Listing

Publication Analysis

Top Keywords

retinal hemorrhage
8
hemorrhage secondary
4
secondary airbag-related
4
airbag-related ocular
4
ocular trauma
4
trauma case
4
case presented
4
presented driver
4
driver wearing
4
wearing three-point
4

Similar Publications

Purpose: Retinal vein occlusion (RVO) is a prevalent retinal vascular disorder characterized by retinal haemorrhage, neovascularization, and macular edema This study aimed to assess the structural and functional effects of intravitreal implant (Ozurdex) treatment as a second-line for RVO-associated macular edema in patients who did not respond to first-line anti-VEGF therapy.

Materials And Methods: We conducted a retrospective observational cohort study using electronic health records of RVO patients at Salisbury District Hospital between January 2014 and December 2019. Inclusion criteria included patients diagnosed with central or branch RVO.

View Article and Find Full Text PDF

The aim of this study was to investigate the locational distribution and potential mechanisms of retinal hemorrhages in newborns using fundus photography. A retrospective analysis of 98 consecutive newborns with retinal hemorrhages in at least one eye and 30 control newborns without retinal hemorrhages after uneventful delivery was conducted. Retinal hemorrhages were diagnosed and characterized using fundus photography and indirect ophthalmoscopy.

View Article and Find Full Text PDF

Retinal hemorrhage (RH) is a significant clinical finding with various etiologies, necessitating accurate classification for effective management. This study aims to externally validate deep learning (DL) models, specifically FastVit_SA12 and ResNet18, for distinguishing between traumatic and medical causes of RH using diverse fundus photography datasets. A comprehensive dataset was compiled, including private collections from South Korea and Virginia, alongside publicly available datasets such as RFMiD, BRSET, and DeepEyeNet.

View Article and Find Full Text PDF

Purpose: To compare the anatomical and visual outcomes in eyes with submacular hemorrhage (SMH) treated with a combination of ranibizumab (RBZ) either innovator or biosimilar (Razumab) and intravitreal perfluoropropane gas (CF).

Methods: Treatment naïve neovascular age related macular degeneration (n-AMD) patients with SMH were retrospectively analyzed. Patients received either innovator or biosimilar RBZ (3 loading doses followed by pro re nata regimen) and single injection of intravitreal CF.

View Article and Find Full Text PDF

A meta-analysis of intravitreal ranibizumab versus laser photocoagulation for the treatment of retinopathy of prematurity.

Ophthalmol Retina

January 2025

Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada; John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Canada. Electronic address:

Purpose: Laser photocoagulation (LPC) has been a traditional treatment for retinopathy of prematurity (ROP). However, intravitreal anti-VEGF agents such as bevacizumab and ranibizumab (IVR) have also been increasingly used. This meta-analysis aims to rigorously compare IVR to LPC in the treatment of ROP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!